Evidence map›Paper›PMID 39550448›Full record

ArticleScientific reports2024

Aspergillus terreus IFM 65899-THP-1 cells interaction triggers production of the natural product butyrolactone Ia, an immune suppressive compound.

Yukiko Ujie, Shun Saito, Keisuke Fukaya, Daisuke Urabe, Takashi Yaguchi, Midori A Arai

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yukiko UjieFaculty of Science and Technology, Keio University, Yokohama, 223-8522, Japan.
Shun SaitoFaculty of Science and Technology, Keio University, Yokohama, 223-8522, Japan.
Keisuke FukayaBiotechnology Research Center, Department of Biotechnology, Toyama Prefectural University, Toyama, 939-0398, Japan.
Daisuke UrabeBiotechnology Research Center, Department of Biotechnology, Toyama Prefectural University, Toyama, 939-0398, Japan.
Takashi YaguchiMedical Mycology Research Center, Chiba University, Chiba, 260-8673, Japan.
Midori A AraiFaculty of Science and Technology, Keio University, Yokohama, 223-8522, Japan. midori_arai@bio.keio.ac.jp.

Funding

the Ministry of Education, Culture, Sports, Science and Technology, Japan 23H04880the Ministry of Education, Culture, Sports, Science and Technology, Japan 23H04884
6 · The paper itself

Abstract

We focused on the possibility that pathogenic microorganisms might produce immune suppressors to evade the action of immune cells. Based on this possibility, we have recently developed new co-culture method of pathogenic actinomyces and immune cells, however, the interaction mechanism between pathogens and cells was still unclear. In this report, co-culturing pathogenic fungi and immune cells were investigated. Pathogenic fungus Aspergillus terreus IFM 65899 and THP-1 cells were co-cultured and isolated a co-culture specific compound, butyrolactone Ia (1). 1 inhibits the production of nitric oxide by RAW264 cells and exhibits regulatory effects on autophagy, suggesting 1 plays a defensive role in the response of A. terreus IFM 65899 to immune cells. Furthermore, dialysis experiments and micrographs indicated that "physical interaction" between A. terreus IFM 65899 and THP-1 cells may be required for the production of 1. This is the first report of co-culture method of fungi with immune cells and its interaction mechanism.

Indexed as

4-ButyrolactoneAspergillusCoculture TechniquesNitric OxideAnimalsAutophagyBiological ProductsHumansMiceRAW 264.7 CellsTHP-1 Cells4-ButyrolactoneBiological Productsbutyrolactone INitric Oxide

Identifiers

PMID39550448
PMCPMC11569209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.